Acute Lung Injury (ALI) – A severe condition marked by widespread inflammation in the lungs, often requiring urgent medical treatment.

Active Pharmaceutical Ingredient (API) – The biologically active component in a drug responsible for its therapeutic effect.

Bioavailability – The proportion of a drug that enters the circulation and can have an active effect.

Biotech – Short for biotechnology, this refers to the use of living systems and organisms to develop or make products, particularly in healthcare and pharmaceuticals.

Cannabidiol (CBD) – A non-psychoactive compound found in cannabis, increasingly used in therapeutic applications for neurological and inflammatory conditions.

Cannabis-Based Therapeutics – Treatments derived from cannabis compounds, such as CBD and THC, used for medical purposes.

Cannabinoids – Chemical compounds found in cannabis that interact with the body’s endocannabinoid system, including CBD and THC.

Chronic Disease – Long-term health conditions, such as epilepsy or autoimmune disorders, that require ongoing management.

Clinical Pipeline – The set of drug candidates a company is developing, typically listed by phase in the clinical trial process.

Clinical Trials – Research studies that test how well new medical approaches work in people, typically divided into phases (I-IV).

Combination Therapy – A treatment approach that uses more than one drug or therapy to treat a single disease.

Compassionate Use – A regulatory pathway that allows patients to access unapproved drugs when no alternatives are available.

Decentralized Clinical Trials – Trials conducted using digital tools and remote monitoring, reducing the need for in-person visits.

Dosage Form – The physical form in which a drug is produced and administered, such as tablets, oils, or oral sprays.

Drug-Resistant Epilepsy – A form of epilepsy that does not respond to standard anti-seizure medications, requiring alternative treatments.

Early Access Program – Programs that allow patients to receive a medicine before it is officially approved.

EMA (European Medicines Agency) – The regulatory authority responsible for the evaluation of medicinal products in the European Union.

Endocannabinoid System – A complex cell-signaling system involved in regulating sleep, mood, appetite, memory, and more; targeted by cannabinoids.

Epilepsy – A neurological disorder characterized by recurrent, unprovoked seizures.

FDA (Food and Drug Administration) – The U.S. agency responsible for protecting public health through the regulation of drugs, vaccines, and other health products.

Formulation – The process in which various chemical substances, including the active drug, are combined to produce a final medicinal product.

GMP (Good Manufacturing Practice) – Regulatory standards that ensure drugs are consistently produced and controlled according to quality standards.

Health Tech – The use of technology to improve healthcare delivery, outcomes, and patient engagement.

High-CBD, Low-THC – A cannabis formulation with high levels of cannabidiol and minimal tetrahydrocannabinol, used for therapeutic purposes with low psychoactive effects.

Immunomodulatory – Refers to substances or treatments that modify the immune response or function.

In-House R&D – Research and development activities conducted internally within a company.

Inflammation – The body’s response to injury or infection, often targeted in therapeutic treatments.

Innovation Pipeline – A company’s sequence of developing products or ideas, from concept to commercialization.

Investment Risk – The potential for loss in financial investments, influenced by market conditions, regulatory changes, and company performance.

Lifecycle Management – The process of managing the commercial, regulatory, and development activities of a drug throughout its life on the market.

Medical Cannabis – The use of cannabis and its constituents for treating medical conditions under supervision and regulation.

Medical Device – An instrument or apparatus used to diagnose, prevent, or treat disease that does not achieve its purpose through chemical action.

Medicinal Chemistry – The science of designing and developing new pharmaceutical agents.

Mental Health – A person’s emotional, psychological, and social well-being; increasingly the focus of biotech innovation.

Mucosal Delivery – A method of drug administration where the drug is absorbed through mucous membranes, such as the mouth.

Nanotechnology – The use of nanoscale materials and devices in science, particularly for drug delivery in healthcare.

Neurological Disorders – Diseases of the brain, spine, and nerves, such as epilepsy and multiple sclerosis.

Orphan Drug – A drug developed specifically to treat a rare disease or condition.

Personalized Medicine – Medical care tailored to the individual characteristics of each patient, including genetic profile and lifestyle.

Phase II Clinical Trials – Studies that evaluate the efficacy and side effects of a drug in a larger group of people after safety has been established.

Pharmacokinetics – The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.

Polypharmacology – The design or use of pharmaceutical agents that act on multiple targets or disease pathways.

Regulatory Approval – Official authorization for a drug to be marketed after passing safety and efficacy assessments.

Refractory Epilepsy – A type of epilepsy that does not respond to conventional treatments.

Therapeutic Indication – The medical condition for which a drug is officially approved for treatment.

Tetrahydrocannabinol (THC) – The primary psychoactive compound in cannabis, often used in combination with CBD for therapeutic purposes.

Well-Tolerated Treatment – A treatment that causes few or no side effects for most patients, contributing to better adherence and outcomes.